Trial ID or NCT#



recruiting iconRECRUITING


This is a prospective, multi-center, double-blind, crossover, randomized controlled trial designed to demonstrate the safety and efficacy of Aluvra for the treatment of GERD.

Official Title

A 12-month Double-blind, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Efficacy of Endoluminal Aluvra™ for the Treatment of Gastroesophageal Reflux Disease

Eligibility Criteria

Ages Eligible for Study: Older than 22 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


John Clarke
John Clarke
Gastroenterologist, Motility specialist
Clinical Professor, Medicine - Gastroenterology & Hepatology

Contact us to find out if this trial is right for you.


Chiara Orlando
(650) 721-8437